Ireland has set a goal to eliminate cervical cancer as a public health problem by 2040. Now 2 years into delivering the HSE’s Cervical Cancer Elimination Action Plan, we are seeing progress across vaccination, cervical screening and treatment, alongside work to make prevention and care more accessible.
Our 2026 progress report highlights important developments in prevention and equity, including reaching more young people with HPV vaccination, expanding access to cervical screening and building evidence of the impact of vaccination.
Seeing the impact of HPV vaccination
HPV vaccination is one of the most effective ways to prevent cervical cancer. It works best when children get it in their first year of secondary school.
In 2026, changes to legislation gave school vaccination teams access to class lists, helping them follow up with students who had not yet been vaccinated. More than 2,000 young people received the HPV vaccine through a national school catch-up campaign launched in January, with further catch-up planned during the 2026/27 school year.
The HSE is also working to address barriers to vaccination. A Community Champions pilot supported 79 people from 8 ethnic groups to get the HPV vaccine. And research with DEIS schools is exploring barriers to vaccination and how communications can be improved.
We are beginning to see the difference vaccination makes. Research found that early HPV vaccination was associated with a 24% reduction in high-grade cytology. Our analysis of vaccination and cervical screening data shows lower rates of cervical disease among those who were vaccinated at the recommended age.
However, HPV vaccination uptake has declined, with coverage among girls falling by 2.8 percentage points between 2022 and 2024. In 2024, 81.2% of girls were vaccinated by age 14, below the World Health Organization (WHO) target of 90% of girls by age 15. 76.1% of boys were vaccinated by age 14. Increasing uptake of the vaccine remains an important priority.
Making cervical screening more accessible
Cervical screening is another important part of preventing cervical cancer. CervicalCheck’s latest published data shows 5-year cervical screening coverage was 75.8% at the end of 2024, above the WHO target of 70%.
We are exploring new ways of making cervical screening more accessible. CervicalCheck and University College Cork’s HPV self-sampling feasibility study received ethical approval in 2026. Working with 5 general practices in urban and rural areas, the study will explore how self-sampling could work in Ireland and potentially provide women with another way to take part in screening.
Reaching people who face barriers to screening
We are also looking at how we can make it easier for people to take part in cervical screening.
The Community Champions for Screening programme trained 19 migrant and Roma workers, 21 social inclusion nurses and 30 key workers in homeless services to support people in their communities to take part in screening.
Since 2023, the CervicalCheck Screening Training Unit has expanded screening beyond GP and community clinics. The number of additional services has grown from 8 to 37 services, with more than 80 trained professionals. This includes sexual health services, prisons, student health services, ambulatory gynaecology services and services supporting women experiencing homelessness.
CervicalCheck is also working with GP practices to encourage women over 50 who are overdue for cervical screening to take part. About 100 practices have joined the initiative to date.
Our CervicalCheck advertising campaign won gold for Best Creative at the 2026 Digital Media Awards. Our entry focused on how creativity helped us make cervical screening feel more human, inclusive, approachable and relevant to a diverse audience.
Improving care and treatment
Ireland is performing well against the WHO target for timely treatment, with 96.7% of people with cervical cancer receiving treatment within one year of diagnosis. This is above the WHO target of 90%.
CervicalCheck's latest reported data for 2023-2024 shows that more than 90% of women were referred to colposcopy within 8 weeks of an abnormal screening result. 8,749 women were treated for high-grade cervical pre-cancers, and 208 women received a diagnosis and ongoing treatment for cervical cancer in colposcopy clinics.
The HSE National Cancer Control Programme worked with primary care and screening partners to improve the journey for women with possible symptoms of cervical cancer, looking at how they are referred and how quickly they can access diagnostic and specialist care.
Tracking Ireland’s progress towards cervical cancer elimination
Cervical cancer incidence in Ireland continues to fall. Ireland’s latest average annual cervical cancer incidence rate was 10.2 new cases per 100,000 women for 2022-2024, compared with 11 per 100,000 for 2021-2023. The WHO defines elimination of cervical cancer as fewer than 4 cases per 100,000 women.
Research and data
This year we strengthened the evidence and data supporting Ireland’s progress towards cervical cancer elimination. Research provided further evidence of the benefits of HPV vaccination at the recommended age and explored HPV self-sampling, screening participation and the barriers faced by communities less likely to take part.
We are also strengthening the data and research needed to monitor progress. We have identified 33 measures to help track Ireland's progress towards elimination and continued preparations for Cara, the new cervical screening register, which is expected to begin operating in 2027.
Together, these developments will help us identify where progress is being made and where further action is needed.
What happens next
Priorities for 2027 include:
- coordinating efforts to address the declining vaccination rates
- continuing HPV vaccination catch-up and the work with DEIS schools
- completing and evaluating the HPV self-sampling feasibility study
- moving to Cara, the HSE’s new cervical screening register
- continuing to improve treatment pathways, clinical guidance and monitoring of progress towards elimination.